EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial

Stefan Zielen iD, Jonathan A Bernstein iD, Gunter J Sturm iD, Marek Jutel iD, Oliver Pfaar iD, RESONATE Investigator Group, Mohamed H Shamji iD, Ralph Mösges iD, Markus Berger iD, Uwe E Berger iD, Lawrence DuBuske iD, Janice A Layhadi iD und 5 weitere

Allergy · 2025

DOI: 10.1111/all.16491 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Allergy, 2025. Verfasst von Stefan Zielen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University Hospital, Goethe University, Frankfurt, Germany. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Seasonal, Allergens, Poaceae, Desensitization, Immunologic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Allergy Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PQ Grass 27600 SU (PQ Grass) cumulative dose is a pre‐seasonal, six‐injection, aluminium‐free, modified subcutaneous immunotherapy product under development for the treatment of allergic rhinitis (AR). A pivotal Phase III randomised double‐blind, placebo‐controlled clinical trial was performed to evaluate the efficacy and safety of PQ Grass in subjects with seasonal AR.

Methods

An adaptive group sequential trial PQGrass306 (G306) with one pre‐defined interim analysis was designed, using 2 parallel groups applying a 1:1 active versus placebo randomisation of patients aged 18–65. The primary efficacy endpoint was the EAACI (European Academy of Allergy and Clinical Immunology) Combined Symptom and Medication Score (EAACI‐CSMS 0–6 ) averaged over the peak grass pollen season (GPS).

Results

858 subjects were screened and 555 subjects were randomised. Based on the results of the pre‐defined interim analysis, the trial was stopped for success showing superiority in favour of PQ Grass. The primary endpoint EAACI‐CSMS 0–6 (peak GPS) demonstrated a highly significant and clinically meaningful point difference of PQ Grass over placebo of −0.27 points (95% CI: −0.42 to −0.12), corresponding to a relative difference of −20.3% ( p = 0.0005). Highly consistent and beneficial results were obtained for PQ Grass for all key secondary endpoints. Significant induction of blocking IgG4 and IgA antibody subclasses occurred. PQ Grass was well tolerated, and no unexpected safety signals occurred.

Conclusions

This pivotal Phase III trial demonstrated a significant and clinically meaningful effect on the primary endpoint as well as highly consistent secondary endpoint results and a supportive safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, Allergic, SeasonalAllergensPoaceaeDesensitization, ImmunologicAdjuvants, ImmunologicHumansAdultFemaleMaleMiddle AgedTreatment OutcomeAdolescentYoung AdultDouble-Blind MethodAgedImmunoglobulin E

Stichwörter der Autor:innen

allergic rhinoconjunctivitisgrass pollen allergypivotal Phase III clinical trialshort‐course treatmentsubcutaneous immunotherapy

Substanzen

AllergensAdjuvants, ImmunologicImmunoglobulin E

Autor:innen und Institutionen

  • Department of Pediatrics, University Hospital, Goethe University, Frankfurt, Germany.
  • Respiratory Research Center Medaimun GmbH, Frankfurt, Germany.
  • Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Bernstein Clinical Research Center, Cincinnati, Ohio, USA.
  • Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
  • Allergy Outpatient Clinic Reumannplatz, Vienna, Austria.

ORCID-Profile: Stefan Zielen, Jonathan A Bernstein, Gunter J Sturm, Marek Jutel, Oliver Pfaar, Mohamed H Shamji, Ralph Mösges, Markus Berger, Uwe E Berger, Lawrence DuBuske, Janice A Layhadi, Ludger Klimek, Markus Ollert, Murray A Skinner, Matthias F Kramer, Pieter-Jan de Kam

Förderung

  • Allergy Therapeutics

Zitieren

APA

Zielen, S., Bernstein, J. A., Sturm, G. J., Jutel, M., Pfaar, O., RESONATE Investigator Group, Shamji, M. H., Mösges, R., Berger, M., Berger, U. E., DuBuske, L., Layhadi, J. A., Klimek, L., Ollert, M., Skinner, M. A., Kramer, M. F., & de Kam, P. J. (2025). Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial. Allergy. https://doi.org/10.1111/all.16491

Vancouver

Zielen S, Bernstein JA, Sturm GJ, Jutel M, Pfaar O, RESONATE Investigator Group, et al. Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial. Allergy. 2025. doi:10.1111/all.16491

BibTeX
@article{Zielen2025,
  author = {Zielen, Stefan and Bernstein, Jonathan A and Sturm, Gunter J and Jutel, Marek and Pfaar, Oliver and RESONATE Investigator Group, RESONATE Investigator Group and Shamji, Mohamed H and Mösges, Ralph and Berger, Markus and Berger, Uwe E and DuBuske, Lawrence and Layhadi, Janice A and Klimek, Ludger and Ollert, Markus and Skinner, Murray A and Kramer, Matthias F and de Kam, Pieter-Jan},
  title = {Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16491}
}
Kostenlos starten →